There are several guidelines addressing the issues around the use of NSAIDs. However, none has
specifically addressed the upper versus lower gastrointestinal (GI) risk of COX-2 selective and non-selective
compounds nor the interaction at both the GI and cardiovascular (CV) level of either class of drugs with low-dose
aspirin. This Consensus paper aims to develop statements and guidance devoted to these specific issues through a
review of current evidence by a multidisciplinary group of experts